The Role of Central Imaging in Successful Oncology Clinical Trials
Today’s oncology R&D programs require precision in early go / no go decisions and clarity on the treatment impact.
Despite the FDA’s guidance on the imaging endpoint process, research shows that variability of site reads vs central reads is typically between 5-30%.
At IAG, we developed and implemented in over 400 trials a modern trial infrastructure for centralized data collection and central imaging review.
In this live webinar, IAG’s imaging experts will share their experience in delivering central review in oncology clinical trials, with enterprise level platform DYNAMIKA that provides efficiencies, compliance, and security in data management. We will show how such a set-up allows to reduce variability in the reads, both radiology assessments and quantitative image review criteria.
We will discuss added efficiencies and cost savings enabled by DYNAMIKA. Our experts will cover advantages of quantitative imaging alongside standard radiographic response criteria, such as RECIST 1.1, iRECIST, RANO, and Lugano.
If you are interested in a replay, please reach out to email@example.com
Key Discussion Points:
- Importance of centralized image interpretation
- Quantitative image analysis and radiological assessments: the need of centralized imaging interpretations
- Choosing the right imaging strategy and platform for your clinical trial.
Followed by a Q&A.
Dr Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer
Medical computer scientist by background, with strong experience in world-class academic research, biotechnology industry, pharma and investment. 10+ years of experience in the strategic use of medical imaging in the assessment of drug efficacy, trial conceptualizing, trial design and de-risking. Actively working with biotech companies to bridge the gap between academic research and their strategy for commercialization.
Sebastien Jacques, IAG’s Senior Project Manager
12+ years of experience in managing central imaging review for oncology clinical trials. Highly skilled in all aspect of Project Management, Software Engineering and Information Technology. Effective management of multiple oncology imaging projects and the project teams from study start-up to database lock with excellent operational planning and oversight, risks mitigation, resource, time and budget planning.
David Chia, CCO and Head of Bio-partnering
Senior executive with over 16 years of experience in strategic clinical development and operational analysis for biotechnology, pharma and life sciences companies. Expertise in creating and maintaining successful strategic partnerships between service providers and sponsors. Highly experienced in all aspects of clinical development including central imaging solutions.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com